The approach goes beyond typical hospital tech implementations. KFSH has built AI into its daily operations, clinical decision-making, and research programs. The hospital says this integration has doubled genomic testing volumes and changed treatment decisions in 70% of cases where genetic insights were applied.

What’s the news?

KFSH has integrated AI across three main areas of hospital operations:

• Command center operations: AI monitors patient flow in real time, predicts capacity issues, and automatically adjusts resource allocation
• Clinical practice: AI helps doctors interpret genetic data faster and make more accurate diagnoses, especially in precision medicine
• Research: AI accelerates gene discovery and helps develop targeted therapies, contributing to global genetic databases

The hospital recently presented its AI integration strategy at the C3 Davos of Healthcare Summit 2026 in California. KFSH officials described their system as an “intelligent healthcare ecosystem” where data and clinical expertise work together.

Why does it matter?

This represents a shift from hospitals using AI for specific tasks to making it central to all operations. Most hospitals today use AI tools for narrow purposes like reading X-rays or scheduling. KFSH’s approach suggests AI can become the backbone of hospital operations.

The results show measurable improvements in patient care. The hospital reports better correction of misdiagnosed cases and treatment decisions that are more personalized based on genetic data. This matters for patients who get faster, more accurate diagnoses and treatments tailored to their genetic makeup.

For the broader healthcare industry, KFSH’s model could show other hospitals how to scale AI beyond pilot projects into full operational integration.

The context

Saudi Arabia has been investing heavily in healthcare technology as part of its Vision 2030 economic diversification plan. The kingdom wants to become a regional hub for medical tourism and advanced healthcare services.

KFSH’s AI push comes as hospitals worldwide struggle with staff shortages and increasing patient volumes. AI-powered command centers and predictive analytics can help hospitals manage these pressures more effectively. The hospital’s focus on genomics also aligns with the growing field of precision medicine, where treatments are customized based on individual genetic profiles.

The hospital’s international recognition – it’s ranked first in the Middle East and North Africa region – gives its AI strategy global credibility. Other academic medical centers are likely watching KFSH’s results as they consider their own AI implementations.

The post Saudi Arabia’s top hospital makes AI central to all operations appeared first on DH Arab.

The treatment targets severe sickle cell disease and transfusion-dependent beta thalassemia. It’s now available for patients aged 12 and older, marking a significant shift from managing these conditions to potentially curing them at their genetic source.

How does it work?

Casgevy uses CRISPR/Cas9 technology – the Nobel Prize-winning gene editing tool – to fix the genetic defects that cause these blood disorders. The process is complex but straightforward in concept:

• Doctors collect the patient’s stem cells through a procedure called apheresis
• The cells are sent to specialized labs where CRISPR technology edits out the genetic problems
• The patient receives chemotherapy to prepare their body for the new cells
• The edited cells are infused back into the patient’s bloodstream
• These cells grow in the bone marrow and start producing healthy red blood cells

“This therapy offers not only hope but the potential for a functional cure, by addressing these diseases at their genetic origin,” said Dr. Chiara Cugno, Acting Chief of Pediatric Hematology at Sidra Medicine.

The hospital has already started treating its first patient and follows about 150 to 200 children in Qatar with these conditions.

Why does it matter?

For patients with severe forms of these diseases, current treatments often fall short. People with severe sickle cell disease face frequent pain crises and stroke risk. Those with transfusion-dependent thalassemia need regular blood transfusions throughout their lives.

Casgevy offers something different – a one-time treatment that targets the root cause rather than just managing symptoms. Early results from global trials show patients achieving independence from blood transfusions and major improvements in quality of life.

“Casgevy is reserved for patients with the most severe form of SCD or TDT – those still experiencing frequent pain crises, stroke risk, or the cumulative burden of lifelong transfusions despite the best medical care,” the hospital explained.

The context

This launch positions Qatar among a select group of countries offering advanced gene therapies. The treatment has approval from major regulators including the U.S. FDA, European Medicines Agency, and Qatar’s Ministry of Public Health.

The move fits Qatar’s broader push into precision medicine – treatments tailored to individual genetic profiles. Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine, called it part of the country’s “precision health vision” where treatment is guided by each patient’s unique genetic makeup.

Vertex Pharmaceuticals, which developed Casgevy, has qualified only a limited number of hospitals worldwide to administer the therapy. The selection reflects the complex infrastructure needed – from specialized cell processing facilities to teams trained in gene therapy protocols.

For the broader Middle East and North Africa region, Qatar’s approval creates a new treatment hub. Eligible children from neighboring countries can now access this therapy closer to home, rather than traveling to Europe or North America.

The post Qatar launches first CRISPR gene therapy for blood disorders appeared first on DH Arab.

The surgeries were performed through Abu Dhabi’s Visiting Physicians Programme, which brings international medical experts to work alongside local teams. German neurosurgeon Prof. Robert Behr led the procedures in collaboration with SSMC’s multidisciplinary team.

How did it work?

Auditory brainstem implants differ significantly from the more common cochlear implants. While cochlear implants work by stimulating the inner ear, ABIs bypass the ear entirely and send electrical signals directly to the brainstem.

The procedure is used when children are born without functional auditory nerves or cochlea, making cochlear implants impossible. The surgery involves:

• Placing electrodes directly on the brainstem’s hearing center
• Creating a pathway for sound signals to reach the brain
• Enabling basic sound perception rather than full hearing restoration

Both children underwent comprehensive clinical evaluations before surgery to determine their suitability for the procedure. The operations required exceptional precision given the complexity of working near the brainstem.

Why does it matter?

The timing of these surgeries is critical. Children develop speech and language skills most effectively during their first few years of life, making early intervention essential for those born with severe hearing impairments.

While ABI doesn’t restore natural hearing, it provides important benefits:

• Basic sound perception that helps children engage with their environment
• Foundation for speech and language development through therapy
• Improved quality of life and social integration opportunities

Dr. Ahmad Al Shamsi from SSMC’s ENT division noted the profound impact on families: “For families, this represents a truly life-changing moment, when a child hears their parents’ voices for the first time.”

The children will require ongoing rehabilitation and speech therapy to maximize the benefits of their implants. Success depends heavily on consistent therapeutic support following the surgery.

The context

This medical milestone fits into Abu Dhabi’s broader strategy to position itself as a regional healthcare hub. The emirate has been investing heavily in specialized medical capabilities and international partnerships to treat complex conditions locally rather than requiring patients to travel abroad.

The Visiting Physicians Programme, launched by Abu Dhabi’s Department of Health, allows local medical teams to learn advanced procedures while providing patients access to world-class expertise. This model helps build long-term capabilities within the UAE’s healthcare system.

ABI surgery remains highly specialized globally, with only select medical centers offering the procedure. The successful completion of these surgeries indicates SSMC’s growing capabilities in complex neurosurgical procedures and positions Abu Dhabi as a destination for specialized pediatric care in the Middle East region.

The post Abu Dhabi performs its first pediatric brain hearing implants on toddlers appeared first on DH Arab.

This marks Vezeeta’s first move into direct facility management, expanding beyond its core business of digital appointment booking and telemedicine services. The company will handle operations for the entire medical building, combining its digital platform with physical healthcare services.

How will it work?

The partnership creates what both companies describe as a fully integrated medical complex within the Prk Vie project. Key elements include:

• Vezeeta’s digital platform will handle appointment bookings and operations management
• Healthcare providers can join the facility through Vezeeta’s network
• The building will be equipped to medical standards set by both partners
• Patients will access services through Vezeeta’s existing digital booking system

“Our goal is to elevate medical service standards and ensure easy access for clients through seamless digital appointment booking and operations management,” said Choucri Asmar, Vezeeta’s Chief Corporate Development Officer.

Why does it matter?

This partnership signals a significant shift for digital health platforms in the region. Rather than just connecting patients with existing clinics, Vezeeta is now directly managing healthcare facilities.

The move comes as Egypt’s medical tourism sector grows, driven by the country’s geographic location and medical expertise. For patients, it promises more streamlined access to healthcare services integrated with digital convenience.

For healthcare providers, the facility offers a premium location in one of New Cairo’s most upscale areas, with built-in access to Vezeeta’s patient network.

The context

Vezeeta operates across the Middle East and Africa, connecting millions of users with healthcare providers in countries including Egypt and Saudi Arabia. The platform offers doctor search, appointment booking, teleconsultation, and medication ordering services.

The company’s expansion into facility management reflects broader trends in digital health, where platforms are moving beyond pure technology plays into hybrid digital-physical models.

Upwyde Developments positions itself as creating integrated lifestyle destinations that combine residential, commercial, and service elements. The Prk Vie project includes business spaces, retail, dining, and residential units alongside the new medical facility.

“This collaboration combines the architectural excellence of the Prk Vie project with Vezeeta’s technological leadership in the healthcare sector,” said Fadel Samir, Co-CEO of Upwyde Developments’ Commercial Sector.

The post Egypt’s Vezeeta partners with real estate developer to open first fully managed medical building appeared first on DH Arab.

The announcement gains extra significance as Saudi Arabia designates 2026 as the Year of Artificial Intelligence, highlighting the country’s push to integrate AI across healthcare and other sectors. For fertility clinics worldwide, AI-assisted selection represents a growing trend to improve success rates and reduce treatment cycles.

How did it work?

The birth followed treatment at Bnoon’s IVF laboratories using an AI system called Vitruvian MD. The technology analyzes sperm through algorithmic assessment, examining three key factors that affect pregnancy success:

• Sperm motility (movement patterns)
• Morphology (physical structure)
• DNA fragmentation (genetic integrity)

In this case, the father had been diagnosed with high DNA fragmentation, a condition that can significantly impact fertility outcomes. Traditional sperm selection relies mainly on visual assessment of movement and shape, but the AI system adds genetic integrity analysis without harming sperm viability.

The technology proves most valuable for severe male fertility issues, including very low sperm counts, poor movement, high DNA damage, or cases requiring surgical sperm retrieval. Clinical data from Bnoon over twelve months, involving more than 50 couples, showed improved fertilization rates compared to conventional selection methods.

Why does it matter?

This development addresses a critical need in fertility treatment: reducing failed IVF cycles. Each unsuccessful attempt costs patients time, money, and emotional strain. AI-assisted selection aims to improve the odds by choosing the healthiest sperm for fertilization.

“The integration of AI into fertility treatment helps reduce the number of repeated failed cycles, improving efficiency and potentially lowering both the time and cost associated with assisted reproductive procedures,” said Majd Abu Zant, Chief Executive of Global Fertility and Chairman of Bnoon.

The technology also standardizes selection processes across different embryologists and clinics. Human assessment can vary between specialists, but AI provides consistent analytical criteria. Dr. Abdulaziz Alshahrani, Bnoon’s Group Medical Director, emphasized that the system “enhances selection precision, particularly in complex cases.”

The context

Saudi Arabia’s fertility sector has grown rapidly as part of the Kingdom’s Vision 2030 healthcare modernization goals. Bnoon now performs over 5,000 IVF cycles annually across centers in Riyadh, Jeddah, and Al Ahsa, with planned expansions to Abha and Madinah.

The network is building a new flagship facility in Riyadh spanning 3,800 square meters, expected to open in the first half of 2024. The center will combine AI, robotics, and genetic testing with broader women’s health services.

Globally, fertility clinics increasingly adopt AI tools to improve success rates and reduce treatment burden on patients. The technology spans embryo selection, ovarian stimulation protocols, and now sperm analysis. As research expands and costs decrease, AI integration is becoming standard practice rather than experimental treatment.

The Saudi announcement comes as the Kingdom positions itself as a regional leader in healthcare innovation, with AI development central to its economic diversification strategy.

The post Saudi Arabia’s first AI-assisted IVF baby born using sperm selection technology appeared first on DH Arab.

The findings open new possibilities for detecting eye diseases before symptoms appear. Healthcare providers can now identify high-risk individuals earlier and design more targeted prevention strategies.

Highlights

• Study analyzed genomic data from 500,000+ Emirati citizens
• Identified approximately 100 genetic causes of inherited vision loss
• Research conducted by M42 and Department of Health – Abu Dhabi
• Data came from the Emirati Genome Programme, one of the world’s largest national sequencing initiatives
• Findings enable identification of high-risk individuals before symptoms develop
• Study highlighted specific genes like ABCA4, linked to Stargardt disease and progressive central vision loss

Why does it matter?

This research represents a major shift from treating eye diseases after they cause symptoms to preventing them entirely. Early detection of genetic risk factors allows doctors to start monitoring patients sooner and potentially slow or prevent vision loss.

The study also demonstrates how large-scale population genomics can complement traditional medical research. Instead of studying small groups of patients, researchers can now analyze health patterns across entire populations to find rare but treatable conditions.

For patients, this means more personalized care. Genetic counseling and targeted monitoring can begin years before traditional diagnosis methods would detect problems.

The context

The UAE has been building one of the world’s most comprehensive national genome databases. The Emirati Genome Programme has now sequenced more than 850,000 genomes, making it among the largest population-scale genomic studies globally.

This research connects genetic information with real health records through Malaffi, the UAE’s health information exchange platform. The secure linking of genetic and clinical data allows researchers to translate scientific discoveries into practical medical applications.

Abu Dhabi is positioning itself as a leader in predictive healthcare – using data and advanced science to prevent diseases rather than just treat them. This eye disease study is part of a broader transformation toward preventive care models that could improve quality of life and reduce long-term healthcare costs.

“This study reflects Abu Dhabi’s commitment to harnessing advanced science and health data to accelerate the shift towards a more preventive and proactive model of care,” said Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi.

The post UAE study finds 100 genetic causes of inherited blindness in national population appeared first on DH Arab.

The model targets biochemistry, drug discovery, and translational medicine research. It can query databases, read scientific papers, connect to other research tools, and suggest new experiments. GPT-Rosalind is built on top of OpenAI’s latest internal models and is available through ChatGPT, Codex, and the API for qualified customers.

How does it work?

GPT-Rosalind supports several key research functions that typically require significant time and expertise:

• Evidence synthesis from multiple sources
• Hypothesis generation based on existing research
• Experimental planning and design
• Database queries across scientific literature
• Integration with over 50 scientific tools and data sources

OpenAI is also launching a free Life Sciences research plugin for Codex that connects scientists to these tools and databases. The model is designed to help researchers accelerate the early stages of discovery by handling routine tasks and providing research suggestions.

Why does it matter?

The pharmaceutical and biotech industries are increasingly turning to AI to speed up drug discovery, which traditionally takes over a decade and costs billions of dollars. Major companies including Amgen, Moderna, and Thermo Fisher Scientific are already working with OpenAI to integrate GPT-Rosalind into their research workflows.

This represents a significant push by OpenAI into specialized AI applications beyond general-purpose chatbots. The company is betting that domain-specific models will be more valuable to enterprise customers than general-purpose tools. For researchers, the model could reduce the time spent on literature reviews and experimental planning, allowing them to focus on actual discovery work.

The context

GPT-Rosalind comes just days after OpenAI announced GPT-5.4-Cyber, a model fine-tuned for cybersecurity work. This pattern of releasing specialized models reflects growing competition in the AI space, particularly with Anthropic’s recent announcement of its Mythos frontier AI model.

The timing is significant for the life sciences industry, which has seen a surge in AI adoption since the COVID-19 pandemic demonstrated the potential for accelerated research timelines. Traditional drug discovery processes remain slow and expensive, with high failure rates that AI tools promise to improve through better target identification and hypothesis testing.

The post OpenAI launches GPT-Rosalind AI model for life sciences research appeared first on DH Arab.

The case highlights both the potential and risks of patients using AI for medical guidance. While Phoebe eventually got her correct diagnosis, medical experts warn that AI chatbots can provide inconsistent health advice that may be dangerous if not discussed with healthcare professionals.

How did it work?

Phoebe’s medical journey started in childhood with mobility issues. She had a limp from birth and balance problems, which doctors initially attributed to her being born without a hip socket. At 19, she collapsed and had a seizure at work, but doctors blamed anxiety.

Her symptoms worsened over several years:

• 2022: Diagnosed with epilepsy and given medication
• December 2024: Could not keep epilepsy medication down, leading to more seizures
• January 2025: Fell down stairs, spent three months in hospital with inconclusive tests
• July 2025: Major seizure left her in a coma for three days

After waking from the coma, a doctor told her she didn’t have epilepsy after all – it was anxiety. That’s when Phoebe decided to input her symptoms into ChatGPT.

The AI chatbot returned a list of possible conditions, including hereditary spastic paraplegia. Despite initial hesitation, Phoebe brought this suggestion to her GP, who agreed it was plausible. Genetic testing confirmed the diagnosis.

Why does it matter?

This case shows how AI tools might help patients advocate for themselves when facing diagnostic challenges. The NHS says hereditary spastic paraplegia is often misdiagnosed because it’s so rare that exact patient numbers are unknown.

However, medical experts stress the risks of self-diagnosis through AI. Dr. Rebeccah Tomlinson, a GP in Cardiff, says AI can be a helpful starting point for conversations with doctors, but patients still need professional medical guidance.

The case also reflects broader pressures on healthcare systems. As Dr. Tomlinson notes: “It’s difficult for GPs to know everything. With the pressure on the NHS, we have to know even more.”

The context

AI chatbots are increasingly being used for health advice, with 230 million people asking ChatGPT health-related questions every week according to OpenAI. Earlier this year, a University of Oxford study found these tools provide mixed results – some good advice, some bad – making it hard for users to know what to trust.

OpenAI launched a new ChatGPT Health feature in the US in January that can analyze medical records, though the company says it’s meant to “support, not replace, medical care.” It’s unclear when or if this feature will reach the UK.

For Phoebe, the diagnosis has been life-changing. She can no longer work as a special educational needs teacher and now uses a wheelchair. But she’s found new direction, studying for a psychology masters degree because she still wants to help people. Her condition can be managed through physiotherapy, and she says having a proper diagnosis finally allows her to plan for the future with confidence.

The post ChatGPT helped identify woman’s rare condition after years of medical misdiagnosis appeared first on DH Arab.

However, the money concentrated around a narrow set of category leaders. Mega-rounds of $100M or more accounted for 60% of all funding across just 19 deals — the highest share in recent quarters. Average deal size climbed to $29.6M, up 46% year-over-year, as investors made fewer but bigger bets.

Highlights

• Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022
• 19 mega-rounds captured 60% of all capital raised
• Eight new unicorns emerged — the most since Q2 2022
• M&A deal count jumped 47% to 56 transactions
• CMS prior authorization deadline driving investment activity
• Pharma committed billions to AI drug discovery platforms
• Healthcare AI hiring surged as competition broadens

Why does it matter?

This data reveals a digital health sector reorganizing around proven winners. The concentration of capital in mega-rounds shows investors have become more selective, focusing on companies with demonstrated scale and commercial success rather than early-stage potential.

The trend has major implications for the industry. Well-funded unicorns like Devoted Health and Alan can now stay private longer, build distribution, and acquire competitors rather than be acquired. This creates a two-tier market where the top companies pull further ahead while smaller players struggle for funding.

The CMS prior authorization mandate, requiring fully electronic systems by January 2027, is also creating urgent investment opportunities. Companies that solve this regulatory requirement face a clear market deadline, making them attractive targets for both investors and acquirers.

The context

Digital health has been recovering from the funding crash of 2022-2023, when investor enthusiasm cooled after pandemic-era highs. The Q1 2026 results suggest the sector has found its footing, but only for companies that can prove real-world adoption and revenue growth.

The M&A activity tells this story clearly. Abbott’s $23B acquisition of Exact Sciences wasn’t just about regulatory approval — Exact’s Cologuard had already completed 20 million screenings with Medicare coverage. Meanwhile, companies with regulatory clearance but minimal revenue struggled to command premium valuations.

In AI drug discovery, the split between large pharma deals and early-stage funding reflects different strategies. Established players like Earendil Labs ($787M raise) and partnerships with Takeda (up to $1.7B committed) focus on compressing existing R&D timelines. Early-stage companies are betting on entirely new drug classes and modalities.

The hiring surge in healthcare AI, led by companies like Tennr and Hippocratic AI, signals the market moving from product development into enterprise deployment. Even tech giants like Anthropic and Nvidia are expanding healthcare-focused roles, suggesting 2026 will see increased competition for healthcare AI talent and market share.

The post Digital health funding surges to $7.4B in Q1 2026, but mega-rounds dominate investment landscape appeared first on DH Arab.

The feature went live on Yelp’s iOS app this week, allowing users to tap “Book now” on provider business pages or use the “Book appointment” option in Yelp Assistant, the platform’s AI chatbot. Users can then view real-time availability and schedule appointments through Zocdoc’s booking system.

How does it work?

The booking process works through these steps:

• Users search for healthcare providers on Yelp as usual
• They can tap “Book now” on provider business pages or ask Yelp Assistant to book an appointment
• The system shows real-time availability from in-network providers
• Users complete the booking through Zocdoc’s secure scheduling system

The feature is currently available on Yelp’s iOS app on provider business pages and through Yelp Assistant. Android and desktop support for business page booking will arrive later this year, with Yelp Assistant booking on Android also coming soon.

For healthcare providers, the integration connects to their existing scheduling systems. Appointments get managed through their current EHR systems or Zocdoc, without requiring changes to their workflow.

Why does it matter?

This partnership addresses a common problem in healthcare: the gap between wanting care and actually getting it. “Healthcare too often breaks at the start, when patients are ready to act but can’t easily transact,” said Oliver Kharraz, Zocdoc’s founder and CEO.

The integration offers several benefits:

• Patients can act on their healthcare research immediately instead of having to call offices during business hours
• Providers can fill appointment slots more efficiently by capturing demand when it happens
• The booking process becomes as simple as making restaurant reservations

“We’re reducing friction and helping providers reach patients through a platform they already trust,” said Craig Saldanha, Yelp’s Chief Product Officer.

The context

This partnership reflects broader changes in how healthcare companies are thinking about patient access. Instead of just running their own platforms, companies like Zocdoc are becoming the infrastructure that powers booking across multiple touchpoints.

Yelp processes millions of healthcare-related searches each week, making it a significant source of patient demand. However, those searches typically ended with users having to call offices during business hours or visit provider websites separately. The Zocdoc integration removes that extra step.

The move also shows how AI assistants are becoming more practical for specific tasks. Yelp Assistant can now complete the entire process from answering health questions to booking actual appointments, rather than just providing information.

For Zocdoc, the partnership continues its strategy of expanding beyond its own marketplace. The company already powers scheduling for insurance directories, provider websites, and phone systems. By becoming the scheduling infrastructure for other platforms, Zocdoc can reach patients wherever they start their healthcare search.

The post Yelp users can now book doctor appointments directly through Zocdoc integration appeared first on DH Arab.